Trial
NCT03091478
Pembrolizumab in Patients With Leptomeningeal Disease
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
Merck Sharp & Dohme LLC
Condition
Patients With Leptomeningeal Disease
Intervention
Pembrolizumab
Why stopped
Low Accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-01-26